RAPP directors buy heavily as earnings loom nine days out

Rapport Therapeutics enters its November 6 earnings print with an unusual signal cutting against the defensive tone of recent weeks: the board is buying the stock with conviction.

Five directors made open-market purchases on October 22, none under a 10b5-1 plan, spending a combined total led by director Steven Paul's $974,000 purchase of 35,714 shares at $27.28. The CFO added 5,500 shares the following day. The cluster is the kind of coordinated insider buying that is hard to dismiss as routine, coming with the stock down 19% over the past month and sitting nearly 50% below the consensus analyst price target. Net insider activity over 90 days remains negative in aggregate, at minus $5.4 million, but that figure is dominated by the CEO's pre-arranged 10b5-1 plan sales. Stripping those out, the discretionary signal this week points one direction only.

The options market is less bullish, though the defensive peak has clearly passed. The put/call ratio has eased to 1.03, down from the 1.31 reading flagged in last week's note. It remains above the 20-day average of 0.97, so puts still outweigh calls, but the z-score has fallen to 0.35, well inside one standard deviation. Investors are still carrying downside protection, they are just less urgently adding to it than they were. The 52-week range on the PCR runs from 0.15 to 3.07, so the current level reads as mild caution rather than genuine fear.

Short positioning is not the driving story here. Bears hold around 6.7% of the free float, flat on the week and up roughly 44% in share count over the past month as the stock sold off from its pre-readout highs. That share of float is elevated but not extreme for a clinical-stage biotech. The borrow market remains wide open: availability has tightened from over 1,100% a week ago to around 822%, still a high multiple of short interest, and cost to borrow has edged up to 0.50% from 0.40%, a 25% weekly move that leaves it firmly in the low-cost band. There is no squeeze pressure in the lending market.

The Street has rarely been more constructive, at least on paper. Seven analysts moved or initiated on RAPP in the past two weeks, every one at Buy or Outperform, with targets ranging from $50 to $89. Jones Trading raised its target from $50 to $82 on October 21. BTIG lifted from $75 to $89 the day before. The mean target is $68, against a stock at $27.54, a gap that ranks RAPP in the 99th percentile for analyst recommendation divergence from price. The bull case rests on RAP-219's phase 2a seizure data, a 77.8% median seizure reduction and 10% discontinuation rate in a refractory population, with a phase 3 epilepsy programme now running and $436 million in cash to fund it into 2H29. Bears counter that the mania thesis is unproven, that no AMPA-NAM has demonstrated randomised antimanic efficacy, and that the stock's drop from $52 to the low $30s after the readout revealed mania as optionality rather than a core value driver.

Wikipedia attention around Rapport has spiked sharply, with a z-score of 4.3 against the prior 90-day baseline as of October 21. That is a retail attention signal, not a revenue indicator, but it confirms the stock is drawing interest well beyond its usual audience, consistent with the insider buying headlines and the approaching earnings date.

With the November 6 print now nine days away, the question is whether the board's collective conviction at $26 to $27 per share holds as a reference point, or whether the earnings data shifts the frame entirely. The price reaction to the last four prints has ranged from minus 4% to plus 10% on day one, and the phase 3 programme update will be the focus.